IBRX (ImmunityBio) Buyback Yield % : -4.78 (As of Apr. 24, 2025)

View and export this data going back to 2021. Start your Free Trial

What is ImmunityBio Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

ImmunityBio's current buyback yield was -4.78%.

ImmunityBio Buyback Yield % Historical Data

The historical data trend for ImmunityBio's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunityBio Buyback Yield % Chart

ImmunityBio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Buyback Yield %

Get a 7-Day Free Trial

-6.80

-2.83

-3.27

-5.10

ImmunityBio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Buyback Yield %	Get a 7-Day Free Trial															-3.27	-1.73	-1.21	-0.50	-5.10

Competitive Comparison of ImmunityBio's Buyback Yield %

For the Biotechnology subindustry, ImmunityBio's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmunityBio's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmunityBio's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where ImmunityBio's Buyback Yield % falls into.

Save Embed

;

Save Embed

;

ImmunityBio Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

ImmunityBio's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	111.357)	/	2183.43424
	=	-5.10%

ImmunityBio's annualized Buyback Yield for the quarter that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock		(TTM)		/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	(TTM)^**	/	Market Cap
	=	- (0	+	111.357)		/	2183.43424
	=	-5.10%

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

ImmunityBio Buyback Yield % Related Terms

Thank you for viewing the detailed overview of ImmunityBio's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmunityBio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunityBio Inc (NAS:IBRX) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

26CA:Germany

Address

3530 John Hopkins Court, San Diego, CA, USA, 92121

Website

https://www.immunitybio.com

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Executives

Patrick Soon-shiong	director, 10 percent owner, officer: See remarks	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
California Capital Equity, Llc	10 percent owner	10182 CULVER BOULEVARD, CULVER CITY CA 90232
Nant Capital, Llc	10 percent owner	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Cambridge Equities, Lp	10 percent owner	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Mp 13 Ventures, Llc	10 percent owner	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Michael D Blaszyk	director	C/O NANTKWEST, INC., 2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
John Owen Brennan	director	C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Wesley Clark	director	C/O ARGYLE SECURITY ACQUISITION CORP., 200 CONCORD PLAZA, SUITE 700, SAN ANTONIO TX 78216
Regan J Lauer	officer: Chief Accounting Officer	4250 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA 92037
Richard Adcock	officer: Chief Executive Officer	C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Cheryl Cohen	director	C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Linda Maxwell	director	1040 SPRING STREET, SILVER SPRING NC 27709
Christobel Selecky	director	C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
David C. Sachs	officer: Chief Financial Officer	C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Frederick W Driscoll	director